GlassScriptPhysician profile
Tomas Salazar
NPI 1699204701
$10,064.26
in general payments reported to CMS, 2019-2025
20 companies · $578 in 2025
The $578 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $208 · 2022: $215 · 2023: $1,388 · 2024: $7,676 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,714 · Food and Beverage: $3,928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,713.73 |
| Food and Beverage | $3,928.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,682.12 | 2023-2025 | Proclaim |
| Saluda Medical Americas, INC. | $2,127.55 | 2024-2025 | Evoke |
| Abbvie INC. | $575.34 | 2022-2025 | Ubrelvy, Qulipta, Botox |
| Boston Scientific Corporation | $314.34 | 2023-2025 | Wavewriter Alpha Prime 16, Intracept, General - Angioplasty |
| Spr Therapeutics, INC | $233.14 | 2023-2024 | Sprint Pns System |
| Bioventus LLC | $183.18 | 2023 | Stimrouter Implantable Kit |
| Jazz Pharmaceuticals INC. | $147.38 | 2023 | Epidiolex |
| Pfizer INC. | $138.31 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $116.11 | 2023-2025 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $65.04 | 2022-2024 | Ztlido |
| Lundbeck LLC | $46.34 | 2023-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $33.62 | 2022 | |
| Stryker Corporation | $31.81 | 2025 | Optablate, Spinejack, Mild Device Kit |
| Medtronic, INC. | $29.28 | 2022 | |
| Globus Medical, INC. | $29.03 | 2025 | Senza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $28.73 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Biohaven Pharmaceutical Holding Company LTD. | $23.52 | 2022 | |
| Impel Pharmaceuticals INC. | $22.33 | 2023 | Trudhesa |
| Supernus Pharmaceuticals, INC. | $16.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.38 | 2024 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomas Salazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.